Fig 1: TPD52 is a target of miR-224-5p. (A) TargetScanHuman was used to predict the binding sequence between TPD52 and miR-224-5p. (B) Luciferase activity of TPD52 3'-UTR-WT and TPD52 3'-UTR-MUT in the presence of miR-224-5p mimic or mimic control. (C) mRNA and (D) protein expression of TPD52 in U251 cells transfected with miR-224-5p mimic or mimic control. **P<0.05 vs. mimic control. TPD52, tumor protein D52; miR-224-5p, microRNA-224-5p; MUT, mutant, WT, wild-type; 3'UTR, 3'untranslated region; NS, not significant.
Fig 2: The miR-224-5p/TPD52 axis may be a functional mechanism of FTH1P3 in glioma. (A) TPD52 expression in low- and high-grade glioma tissues and adjacent normal tissues. (B) The expression of TPD52 in glioma U251 cells treated with mimic control, miR-224-5p mimic, miR-224-5p mimic + blank control, miR-224-5p mimic + pc-TPD52. (C) The cell viability of each group after 24, 48 and 72 h was determined by MTT assay. (D) A BrdU incorporation assay showed BrdU-positive cells in different transfected groups (magnification, ×400). (E) The percentage of apoptotic cells in each group was detected by flow cytometry. (F) Western blot analysis showed the expression levels of BAX/BCL2 in different transfected groups. (G) Schematic representation of the potential mechanism of action of lncRNA FTH1P23 in glioma. *P<0.05, **P<0.01 and ***P<0.001. lncRNA, long non-coding RNA; FTH1P3, ferritin heavy polypeptide 1 pseudogene 3; BrdU, 5-bromo-2-deoxyuridine; BAX, apoptosis regulator BAX; BCL2, B cell lymphoma 2; TPD52, tumor protein D52; miR-224-5p, microRNA-224-5p.
Supplier Page from Abcam for Anti-TPD52 antibody [EPR14219]